Key Highlights
- $12 million Series C financing round co-led by SymBiosis and Khosla Ventures.
- Funds to support clinical development of STMC-103H, aimed at preventing atopic diseases in newborns.
- Siolta receives NIH grant for necrotizing enterocolitis program, collaborating with Johns Hopkins University.
Source: Business Wire
Notable Quotes
- “This Series C financing is a key step for Siolta as we continue to develop STMC-103H in the clinic.” – Dr. Nikole E. Kimes, CEO and Co-founder at Siolta Therapeutics
- “Our continued investment in Siolta Therapeutics reflects our confidence in the company’s ability to advance the development of STMC-103H.” – Aleksei Cremo, Vice President at SymBiosis
- “Siolta’s novel approach is a game changer for drug development.” – Samir Kaul, Founding Partner and Managing Director at Khosla Ventures
SoHC's Take
Siolta Therapeutics’ recent $12 million Series C financing round marks a significant milestone in the development of live microbiome-based therapeutics. The investment underscores the growing interest in leveraging the microbiome to prevent and treat diseases, particularly in vulnerable populations such as newborns. Siolta’s lead product, STMC-103H, represents a pioneering approach to addressing the root causes of atopic diseases from an early age. This financing, alongside the NIH grant for the STMC-106 program, positions Siolta to further its mission of developing safe and effective treatment options. The involvement of esteemed investors and institutions highlights the potential of Siolta’s innovative therapies to transform healthcare outcomes for maternal and infant health.
